Latuda朗舒達

Latuda Drug Interactions

Manufacturer:

Sunovion

Distributor:

DKSH
Full Prescribing Info
Drug Interactions
Potential for Other Drugs to Affect LATUDA: LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) (see Contraindications). The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose (see Dosage & Administration).
Lithium: It is not necessary to adjust the LATUDA dose when used concomitantly with lithium (Figure 2).
Grapefruit: Grapefruit and grapefruit juice should be avoided in patients taking LATUDA, since these may inhibit CYP3A4 and alter LATUDA concentrations (see Dosage & Administration).

Click on icon to see table/diagram/image

Potential for LATUDA to Affect Other Drugs: No dose adjustment is needed for lithium or substrates of P-gp, CYP3A4 (Figure 3) when coadministered with LATUDA.

Click on icon to see table/diagram/image
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in